A rapid immune response to 2009 influenza a(H1N1) vaccines in adults: A randomized, double-blind, controlled trial

Journal of Infectious Diseases

Volumn 202, Issue 5, 2010, Pages 675-680

  Wu, Jiang ^a   Li, Wei ^b   Wang, Hua Qing ^c   Chen, Jiang Ting ^d   Lv, Min ^a   Zhou, Ji Chen ^e   Liang, Xiao Feng ^c   Fang, Han Hua ^b   Liu, Yan ^d   Liu, Li Ying ^e   Wang, Xu ^d   Zhang, Wu Li ^e   Zhang, Xiao Mei ^d   Song, Li Fei ^d   Qiu, Yuan Zheng ^d   Li, Chang Gui ^b   Wang, Jun Zhi ^b   Wang, Yu ^c   Yin, Wei Dong ^d  

^a Beijing Centers for Diseases Control and Prevention   (China)

^b National Institute for the Control of Pharmaceuticals and Biological Products   (China)

^c Centers for Disease Control   (China)

^d Sinovac Biotech Co Ltd   (China)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; INFLUENZA VACCINE;

ABDOMINAL PAIN; ADULT; ALLERGY; ANGINA PECTORIS; ANOREXIA; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LOGISTIC REGRESSION ANALYSIS; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VIRION; YOUNG ADULT;

EID: 77955683120     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655226     Document Type: Article

References (13)

1. World Health Organization. DG Statement following the meeting of the Emergency Committee. http://www.who.int/csr/disease/swineflu/ 4th-meeting-ihr/en/index.html. Published 11 June 2009. Accessed 5 August 2009.
2. World Health Organization. Pandemic (H1N1) 2009-update 81. http:// www.who.int/csr/don/2009-12-30/en/index.html. Published 30 December 2009. Accessed 31 December 2009.
3. Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351:472-477.
4. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-589.
5. Wu J, Fang HH, Chen JT, et al. Immunogenicity, safety, and crossreactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009; 48:1087-1095.
6. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-2413.
7. Zhu FC, Wang H, Fang HH,et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-2423.
8. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-48.
9. World Health Organization. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development X-179A. http://www.who.int/csr/resources/publications/swineflu/candidates-X-179a/en/ index.html. Published 27 May 2009. Accessed 20 August 2009.
10. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-997.
11. Division of Microbiology and Infectious Diseases. Adult toxicity table. http://www.niaid.nih.gov/labsandresources/resources/DMIDClinRsrch/toxtables.htm. Published 21 November 2007. Accessed 20 August 2009.
12. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London, United Kingdom: European Agency for the Evaluation of Medicinal Products, 1997.
13. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375: 56-66.